Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HELEN-001): results from a multicenter, randomized controlled, open-label phase II trialZhenzhen Liu, Xiuchun Chen, Xianfu Sun et al.|Research Square|2024Cited by 0
Abstract PO1-28-07: Neoadjuvant docetaxel plus cisplatin versus docetaxel plus doxorubicin and cyclophosphamide in early-stage triple-negative breast cancer (HNBC-001): results from a multicenter, randomized controlled, open-label phase II trialDechuang Jiao, Zhenzhen Liu, Jianghua Qiao et al.|Cancer Research|2024Cited by 0